A proof-of-concept, single-arm, phase II clinical trial, led by investigators from the Mass General Cancer Center, reported a long-lasting response among patients who responded to the combined treatment and reveals how a targeted therapy may cooperate with an immunotherapy for better results.
Cleveland Clinic-led research has identified geographic areas in the United States where strategic efforts to promote colorectal cancer screening could help reduce health care gaps affecting Hispanic/Latino communities.
